Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
Rhythm Pharmaceuticals (NASDAQ:RYTM) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones [Yahoo! Finance]